Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 20Glioblastoma 5Endometrial Neoplasms 5Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Neoplasms 3Leukoplakia, Oral 3Insulin Resistance 3Ovarian Neoplasms 2Obesity 2Metabolic Syndrome 2Metabolic Diseases 2Medulloblastoma 2Infertility 2Erythroplasia 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Intraductal, Noninfiltrating 2Adenocarcinoma Of Esophagus 2Weight Loss 1Uterine Cervical Neoplasms 1Urothelial Cancer 1Thyroid Diseases 1TP53 Y220C Mutation 1Smoldering Multiple Myeloma 1Sarcoma 1Rectal Neoplasms 1Prostate Cancer Recurrent 1Prediabetic State 1Posterior Fossa Ependymal Tumor 1

Interventions

Carboplatin 5pembrolizumab 3Paclitaxel 3Observation 3Capecitabine 3Azacitidine 3venetoclax 2pertuzumab 2olaparib 2durvalumab 2Tretinoin 2Trastuzumab 2Standard of Care 2Oxaliplatin 2Irinotecan 2Immunotherapy 2Chemoradiotherapy 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1tegafur-gimeracil-oteracil 1taxane 1talazoparib 1tagraxofusp 1sarilumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Metformin × 1 year × Clear all
NCT06728982 2025-08-01

Impact Of Metformin In Rectal Cancer Patients

Minia University

Phase 2/3 Completed
85 enrolled

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon âš¡